Your Messages Inbox
Your Article Summary
See Latest ArticlesNIAID News Release: Statement: Early Results from Clinical Trials of 2009 H1N1 Influenza Vaccines in Healthy Adults
National Institute of Allergy and Infectious Disease - News, 09/14/09
The slight discrepancies seen in our trials between the Sanofi Pasteur and CSL Limited vaccines may be due to technical differences in the preliminary measurement of the amounts of antigen in the doses used in the clinical trial lots and the relatively limited numbers of samples studied to date, as well as the fact that our data are drawn from a very early time point after immunization.
Related Articles
Update on 2009 pandemic influenza A (H1N1) virus
Cleveland Clinic Journal of Medicine, 10/05/09
Relevance Score: 92%
The pandemic 2009 (H1N1) swine influenza virus is mild compared to the pandemic 1918 (H1N1) virus because of a proline-to-serine substitution in the receptor-binding site of its hemagglutinin ? A hypothesis
Medical Hypotheses, 10/19/09
Relevance Score: 91%
One Dose of H1N1 Vaccine Immunogenic in High Percentage of Youth Ages 10 to 17. Younger Children Likely Will Need Two Doses
American Family Physician, 10/05/09
Relevance Score: 91%
H1N1 Vaccine Deliveries Begin. Early Doses to Arrive This Week
American Family Physician, 10/07/09
Relevance Score: 90%
The first Pandemic of the 21st Century: A Review of the 2009 Pandemic Variant Influenza A (H1N1) Virus
Postgraduate Medicine, 10/02/09
Relevance Score: 90%
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
The Unintended Consequences of Clinical Trials Regulations
PLoS Medicine, 12/04/09
Characterization of Baseline Methicillin-Resistant Staphylococcus aureus Isolates Recovered from Phase IV Clinical Trial for Linezolid
Journal of Clinical Microbiology, 12/03/09
Bayer Starts Phase III Trial with Florbetaben
BayNews International, 12/01/09
Article Search
Sponsor